Format
Sort by

Send to:

Choose Destination

Results: 4

1.

Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients.

Engelstaedter V, Heublein S, Schumacher AL, Lenhard M, Engelstaedter H, Andergassen U, Guenthner-Biller M, Kuhn C, Rack B, Kupka M, Mayr D, Jeschke U.

BMC Cancer. 2012 Dec 15;12:600. doi: 10.1186/1471-2407-12-600.

2.

Lack of prognostic relevance of Her-2/neu, topoisomerase IIα and EGFR in advanced ovarian carcinoma.

Engelstaedter V, Boda J, Völklein C, Engel J, Jeschke U, Kirchner T, Mayr D.

Exp Ther Med. 2012 May;3(5):828-834. Epub 2012 Feb 13.

3.

Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.

Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN.

Cancer Genet. 2012 Jan-Feb;205(1-2):34-41. doi: 10.1016/j.cancergen.2012.01.008.

4.

CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients.

Harder J, Engelstaedter V, Usadel H, Lassmann S, Werner M, Baier P, Otto F, Varbanova M, Schaeffner E, Olschewski M, Blum HE, Opitz OG.

Br J Cancer. 2009 Jan 27;100(2):360-5. doi: 10.1038/sj.bjc.6604859. Epub 2009 Jan 13.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk